Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
viral v.non-viral sleeping beauty...seems non-viral is 'better', safer, less expensive...
https://www.nature.com/articles/leu2016180
think intrexon, ziopharm, others...
better dna prediction!
if the usa doesn't get off this non-GMO nonsense kick we will lose the next wave, last wave in medical break-throughs! Adopt better dna science now or forever play catch-up to euro, non-usa companies!
ajimhothough
better dna...intrexon is at the forefront of this medical revolution
http://www.bbc.com/news/health-42402420#
life expectancy will increase by 10 years once these new "better dna's" come to market!
ajimhothough ;)
oxitec solution used in brazil in july 2017
http://oxitec.com/oxitec-launching-friendly-aedes-project-juiz-de-fora-brazil/
epa reviewing for us approval!
FDA issues final Guidance for Industry, transferring regulatory authority to EPA
aquabounty salmon
https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm472487.htm
I hope the bleeeeeeeeeeeding will finally stop on this!
eu & bill gates supporting innovations, genetically engineered agriculture sectorhttps://www.euractiv.com/section/development-policy/news/eu-and-gates-foundation-pledge-e500-million-for-innovations-in-agriculture/
testing recent lows...
watching and will BUY more if we get to my TARGET BUY range.
likely we put in a double-bottom soon from which to rally at year-end and well into early 2018!
ajimhothough
safe genes
https://www.darpa.mil/program/safe-genes
darpa instituting technology safeguards...a good thing for the emerging industry and the world.
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company has market cap of $10.01 million. The companyÂ’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It currently has negative earnings. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.
fibrocell & intrexon gene therapy venture
https://kgazette.com/fibrocell-science-inc-fcsc-reaches-0-68-52-week-low-fil-ltd-has-raised-its-cboe-hldgs-cboe-position/
ZIOPHARM reportrs clinical data from Data from T-Cell Therapy Programs; shows continued survival benefit
5:25 AM ET 12/11/17 | Briefing.com
Co announced data supporting its non-viral approach to rapid manufacture of chimeric antigen receptor (CAR)-modified T cells to treat patients with cancers Two trials demonstrated that first-generation SB-modified CD19-specific CAR+ T cells appear to provide long-term cancer control when infused after hematopoietic stem-cell transplantation (HSCT) for patients with advanced CD19+ malignancies and could be detected years after administration in some recipients. All seven patients with advanced CD19+ non-Hodgkin's lymphoma (NHL) that received autologous T cells were alive at a median survival of 40 months since infusion, with progression-free survival (PFS) reported at 86% and overall survival (OS) at 100%. For 19 patients with advanced CD19+ acute lymphoblastic leukemia (ALL) and NHL infused with allogeneic T cells following HSCT, nine patients were alive with a median survival of 31 months. The PFS rate and OS rates are 32% and 49%, respectively. Of the subset of eight patients who received donor-derived T cells after haploidentical HSCT, PFS and OS rates are 50% and 63%, respectively. Persistence of circulating SB-modified CAR+ T cells was demonstrated at two years in an autologous and allogeneic patient and for four years in two autologous patients.
ZIOPHARM is advancing its non-viral Sleeping Beauty (SB) platform towards point-of-care (P-O-C) for very rapid manufacturing of genetically modified CAR+ T cells. Data presented from first- and second-generation SB clinical trials demonstrate safety, tolerability, disease response, long-term survival, and persistence of infused CD19-specific CAR+ T cells. Preclinical studies showed that P-O-C CAR+ T cells co-expressing membrane-bound interleukin-15 (mbIL15) and a control switch manufactured within two days do not require activation or propagation in tissue culture to achieve anti-tumor effects and prolonged T-cell survival. Building on these data, the Company plans to initiate its first P-O-C clinical trial in 2018.
zeopharm/intrexon t-cell update
http://ir.ziopharm.com/releasedetail.cfm?ReleaseID=1051299
carry on!!! ;)
bioengineered mosquitos approved by epa to combat zika, dengue..!!!
https://seekingalpha.com/news/3310720-epa-oks-release-bioengineered-mosquitoes-20-u-s-states
EPA OKs release of bioengineered mosquitoes in 20 U.S. states
Nov. 9, 2017 3:57 PM ET|By: Douglas W. House, SA News Editor
On November 3, the Environmental Protection Agency (EPA) approved the release of bioengineered mosquitoes in 20 states and the District of Columbia beginning next summer as a tactic to reduce the risk of mosquito-borne diseases like Zika and Dengue.
The Asian Tiger mosquitoes, bred by Lexington, KY-based startup MosquitoMate, contain the bacterium Wolbachia pipientis which interferes with reproduction by preventing paternal chromosomes from fully forming.
Much of the mosquito-infested Southeast is excluded since MosquitoMate has not performed field trials there.
Intrexon's (XON +1.2%) Oxitec is pursuing a similar track with its Friendly Aedes mosquito (OX513A) which are genetically engineered to inherit a gene that causes death before reaching reproductive age.
Verily Life Sciences recently launched a field study in Fresno, CA on its sterile mosquitoes, also Aedes aegypti.
1st sale in June 2017
https://aquabounty.gcs-web.com/node/8326/html
crispr proposed efficiency rules
https://phys.org/news/2017-12-scientists-efficiency-gene-technology.html
all good for the emerging gene editing industry!
fyi...The Washington Post picked up the story as well.
$56B Synthetic Rubber Market in 2020
https://en.wikipedia.org/wiki/Synthetic_rubber
XON just announced that the company is building a plant which will be competed within 18 months to participate and maybe to lead on cost!
Norway's Common-Sense Model for Aquaculture
https://thefishsite.com/articles/norwegian-legislative-debate-offers-hope-for-gene-editing-in-aquaculture
FDA APPROVAL, MARKET APPROVAL NEXT?!?!
https://geneticliteracyproject.org/2017/12/05/anti-biotech-environmental-groups-trying-kill-roll-aquabountys-sustainable-salmon/?mc_cid=c20bae519c&mc_eid=b2383a0fbd
As mentioned in the attached article, this so-called" battle is nothing more than economics, market-share protection and clearly NOT safety-related. THE FDA has "ALREADY' APPROVED the elegantly optimized design and it's selling quite well now. I think that aquabounty will first sell quite effectively and profitably, as mentioned, in select, niche, receptive markets then will expand over time with proven-track records, benefits and efficacy. ajimhothough
https://www.wired.com/story/what-is-crispr-gene-editing
source: WIRED - what is crispr gene editing
excellent WIRED article and video explaining the definitive gene editing tool crispr.
from the video, imagine if one had a disease that could be elegantly cured by gene editing, wouldn't you jump at the chance to stave off the profession of the disease? I believe that I would. now think about genetically optimizing other things in nature that are prudently, safely feasible to optimize, that is what i believe is intrexon's mission, in a nutshell. ajimhothough
11/30/2017 xon ceo insider buys!!!
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11923250&type=HTML&symbol=XON&companyName=Intrexon+Corporation&formType=4&dateFiled=2017-12-04
captain kirk ROCKS!]
xon's "precigen" subsidiary collaborations
with ziopharm!
ziopharm & intrexon pipeline
http://ziopharm.com/pipeline/dna-therapeutics
FDA APPROVAL!
AquaBounty/AquaAdvantage Salmon
I'll have my 8 oz. salmon broiled with herbs & lemon, wild rice and asparagus sides and a sancerre white wine from france.
http://aquabounty.com
AquaBounty Symbol: AQB is a biotech co. focused on enhancing productivity in the aquaculture market and a majority-owned sub of intrexon....trout & tilapia next.
In Nov. 2015 AQB was granted FDS approval for the production, sale and consumption of its AquaAdvantage Salmon - a game-changer that will bring healthy and nutritious food to consumers in an environmentally responsible manner without damaging the ocean and other marine habitats.
The AquaAdvantage fish program is elegantly based on XON's single, molecular modification in fish that results in more rapid growth in early development.
It could happen but this has been so volatile I don't think it would last
14.50 by friday LOL
I thought XON was suppose to be the stock of this decade not the next one.
Synthetic Biology Market Worth $26B by 2025
https://www.medgadget.com/2017/11/synthetic-biology-market-worth-us-26-billion-by-2025-due-to-increasing-demand-for-enhanced-vaccines-and-drugs.html
Book Recommendation on Gene Editing
A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution Kindle Edition
by Jennifer A. Doudna (Author),? Samuel H. Sternberg (Author)
Patents Assigned to Intrexon Corporation
https://patents.justia.com/assignee/intrexon-corporation
GDO, GEO, GOO or GOD
GENETICALLY DESIGNED ORGANISM
GENETICALLY ENHANCED ORGANISM
GENETICALLY OPTIMIZED ORGANISM or
GENETICALLY OPTIMIZED DESIGN....GOD ! ! !
GMO, GENETICALLY MODIFIED ORGANISM...NOT SO MUCH...
LET'S CHANGE THE PERCEPTION OF GENE DESIGN, ENHANCEMENT, OPTIMIZATION...the capability to do so is from...GOD...aimho
Represents intrexon's pre-cut, sliced arctic apples in small bags only...this will be big!!!
Large Market Opportunity in Fruits & Vegetables
Arctic® fresh sliced apples represent Intrexon’s initial non-browning product launch into the commercial marketplace:
Projected outlook for Arctic® fresh apple slices
2020
$20 million sales
2022
$100 million sales >50% GMs
2026
$500 million sales >50% GMs $200 million EBITDA
Non-browning fruits & vegetables under development at Intrexon:
Avocados Pears CherriesLettuce
Alright, bottom is in. Let's rock. $15
Not today. Maybe Friday?
Not today. Maybe Friday
arctic golden apples
commercial launch in q4 2017 !
https://www.arcticapples.com/arctic-apples-r/arctic-golden/
btw..osf is a sub of xon.
RJ KIRK
I really believe that RJ, Captain Kirk needs to do a roadshow on his company since I believe that XON is not well understood by investors & analyst's for that matter...Barron's Biotechnology Roundtable would be an excellent venue. Beam Me Up Scottie! ;) GL
Followers
|
48
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
413
|
Created
|
08/24/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |